|
MONDAY, SEPTEMBER 13
|
Continental Breakfast
6:30 a.m.-8:30 a.m.
|
Meet-the-Expert Sessions 1-2
7:00 a.m.-7:45 a.m.
Funding paradigms in the tumor microenvironment
Dinah S. Singer, National Cancer Institute, Rockville, MD
Hypoxic tumor microenvironment: Validation of novel metabolic targets
Jacques Pouysségur, Institute of Signaling, Developmental Biology, and Cancer Research, Nice, France
|
Plenary Session 2: Translational Targets I
Chairperson: George W. Sledge, Indiana University Cancer Center, Indianapolis, IN
7:45 a.m.-10:15 a.m.
Is the micrometastatic cell a clinical target?
George W. Sledge
Targeting TGF-beta to suppress metastasis
Lalage M. Wakefield, National Cancer Institute, Bethesda, MD
The role of tumor endothelin-1 in metastatic colonization of the lung
Dan Theodorescu, University of Colorado Comprehensive Cancer Center, Aurora, CO
Bone metastasis of lung cancer and its molecular-targeted therapy in the organ microenvironment
Saburo Sone, University of Tokushima Graduate School, Tokushima, Japan
* 14-3-3ζ cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition
Dihua Yu, University of Texas MD Anderson Cancer Center, Houston, TX
* Chemotherapy promotes lung metastasis formation in mouse models via a VEGFR-1-dependent mechanism
Laura G.M. Daenen, University Medical Centre, Utrecht, The Netherlands
|
Break
10:15 a.m.-10:45 a.m.
|
Concurrent Sessions 1-2
10:45 a.m.-12:15 p.m.
-
TME: Stroma
Chairperson: Zena Werb, University of California, San Francisco, CA
Targeting stromal proteases as therapy for cancer
Samuel R. Denmeade, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD
Adult stromal cells for the targeted therapy of gastrointestinal cancers
Pierre Cordelier, Institut Louis Bugnard, Toulouse, France
Role of the tumor microenvironment in breast cancer progression and response to therapy
Zena Werb
-
MRS: Genomics of Primary Tumors and Metastases
Chairperson: G. Steven Bova, Johns Hopkins University School of Medicine, Boston, MA
Exploring clonality in lethal metastatic prostate cancer: Potential value in reducing complexity
G. Steven Bova
Comparing genomics of primary tumors and metastases for targets identification and biomarkers development in lung cancer
Ignacio I. Wistuba, University of Texas MD Anderson Cancer Center, Houston, TX
Epigenetic and microenvironmental regulation of metastatic dispersal in childhood malignancy
Stefan Burdach, Technische Universität München, Munich, Germany
|
Lunch on own
12:15 p.m.-1:15 p.m.
|
Controversy Session: Anti-angiogenesis: Hot or Not?
1:15 p.m.-2:30 p.m.
The biology behind the successes and failures of VEGF-targeted therapies
Lee M. Ellis, University of Texas MD Anderson Cancer Center, Houston, TX
Preclinical modeling of adjuvant and metastatic antiangiogenic (and other drug) therapies
Robert S. Kerbel, University of Toronto Sunnybrook Health Sciences Centre, Toronto, ON, Canada
|
Plenary Session 3: Novel Molecular Pathways
Chairperson: Joan Massagué, Memorial Sloan-Kettering Cancer Center, New York, NY
2:30 p.m.-4:30 p.m.
Correlative biomarkers for anti-angiogenic therapy
Jeffrey W. Clark, Massachusetts General Hospital Cancer Center, Boston, MA
Metastasis meets microenvironment: Survival signals from the soil
Joan Massagué
Necdin regulation by Nm23-H1 and EBNA3C: Insights from a virus
Erle S. Robertson, Abramson Cancer Center of University of Pennsylvania, Philadelphia, PA
*A novel population of Neuropilin-1-Expressing Mononuclear Cells (NEMs) contributes to tumor vessel stabilization and normalization
Alessandro Carrer, ICGEB, Trieste, Italy
* The KISS1 metastasis suppressor appears to reverse the ‘Warburg Effect’™ by increasing mitochondrial number
Kyle P. Feeley, University of Alabama, Birmingham, AL
|
Break
4:30 p.m.-4:55 p.m.
|
Concurrent Sessions 3-4
4:55 p.m.-6:30 p.m.
-
TME: Inflammation and Immunity
Chairperson: Alberto Mantovani, Istituto Clinico Humanitas, University of Milan, Rozzano, Italy
Chemokines in tumor progression and metastasis
Alberto Mantovani
Inflammation and cancer: Reprogramming the immune microenvironment as an anticancer therapeutic strategy
Lisa M. Coussens, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA
Stem cells, inflammation, and tumor immunity: From bedside to the bench
Madhav V. Dhodapkar, Yale School of Medicine, New Haven, CT
* Spatial and temporal regulation of CXCR3 chemokine production and CD8 T cell infiltration in the metastatic melanoma microenvironment
David W. Mullins, University of Virginia, Charlottesville, VA
-
MRS: Metastatic Colonization
Chairperson: Carrie W. Rinker-Schaeffer, University of Chicago, Chicago, IL
Using metastasis suppressors to dissect cancer cell-microenvironmental interactions during metastatic colonization
Carrie W. Rinker-Schaeffer
Novel mediators of tumor-stroma crosstalk in breast cancer bone metastasis
Yibin Kang, Princeton University, Princeton, NJ
* A mutant of the metastasis susceptibility gene Brd4 promotes EMT, stem cell-like conversion and metastatic progression in a mouse mammary tumor model
Jude Alsarraj, National Institutes of Health, National Cancer Institute, Bethesda, MD
Can we screen for anti-metastatic agents?
Bruce R. Zetter, Children's Hospital Boston, Harvard Medical School, Boston, MA
|
Poster Session A
6:30 p.m.-8:30 p.m.
- Genomics of Primary Tumors and Metastases
- Inflammation and Immunity
- The Influence of the Niche
- Metastasis and the Matrix
- Novel Molecular Pathways
- Site Specific Metastasis
- Stem Cells
- Stroma
- Translational Targets
|